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Abstract
This paper aimed at studying the transplacental transmission of HPV and looking at the
epidemiological factors involved in maternal viral infection. The following sampling methods were
used: (1) in the pregnant woman, (a) genital; (b) peripheral blood; (2) in the newborn, (a) oral cavity,
axillary and inguinal regions; (b) nasopharyngeal aspirate, and (c) cord blood; (3) in the placenta.
The HPV DNA was identified using two methods: multiplex PCR of human β-globin and of HPV
using the PGMY09 and PGMY11 primers; and nested-PCR, which combines degenerated primers
of the E6/E7 regions of the HPV virus, that allowed the identification of genotypes 6/11, 16, 18, 31,
33, 42, 52 and 58. Transplacental transmission was considered when type-specific HPV
concordance was found between the mother, the placenta and the newborn or the mother and
cord blood. The study included 49 HPV DNA-positive pregnant women at delivery. Twelve
placentas (24.5%, n = 12/49) had a positive result for HPV DNA. Eleven newborn were HPV DNA
positive in samples from the nasopharyngeal or buccal and body or cord blood. In 5 cases (10.2%,
n = 5/49) there was HPV type-specific agreement between genital/placenta/newborn samples. In
one case (2%, n = 1/49) there was type specific HPV concordance between genital/cord blood and
also suggested transplacental transmission. A positive and significant correlation was observed
between transplacental transmission of HPV infection and the maternal variables of
immunodepression history (HIV, p = 0.011). In conclusion the study suggests placental infection in
23.3% of the cases studied and transplacental transmission in 12.2%. It is suggested that in future
HPV DNA be researched in the normal endometrium of women of reproductive age. The possible
consequence of fetal exposure to HPV should be observed.
Background
Human papillomavirus (HPV), the most common sexu-
ally transmitted infection, has been recognized as a cause
of anogenital warts (HPV type 6 and 11) and cervical can-
cer (HPV type 16, 18 and others)[1]. In children, HPV-
related (type 6 and 11) laryngeal papillomas, conjunctival
papillomas and genital warts [2-6].
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Although it has been established that HPV is sexually
transmitted[7,8], there is growing evidence that non-sex-
ual transmission also occurs[9]. This includes vertical
transmission from parents to infants, horizontal transmis-
sion from other family members and those in close con-
tact with the child, autoinoculation from one site to
another and possibly indirect transmission via phom-
ites[10]. The potential mother-to-child HPV transmission
route in the perinatal period has been demonstrated [11-
17]. There is evidence of vertical transmission, presuma-
bly occurring during passage of the fetus through an
infected birth canal[18]. The virus could also be transmit-
ted by ascending infection, especially after premature rup-
ture of the membranes. In utero transmission could be
caused either by ascending infection from an infected
birth canal, by sperm at fertilization or hematogenously
(transplacentally). HPV DNA has been detected in periph-
eral blood mononuclear cells of pregnant women[19],
cord blood specimens of neonates[19], oropharyngeal
secretions of neonates[20], amniotic fluid [21-23], fetal
membranes[24], placental trophoblastic cells[11], infants
born by elective cesarean section deliv-
ery[11,13,18,22,24], and in syncytiotrophoblastic cells of
spontaneously aborted material[25]. In addition, there
are type-discordant cases between mothers and newborns,
suggesting that many of these infants did not acquire the
HPV from their mothers[26]. These observations could
explain the transplacental transmission of HPV from an
infected mother to the fetus. However, only a limited
number of women have been studied to confirm placental
transmission of HPV.
This cross-sectional, prospective study aimed at evaluating
transplacental transmission of HPV and enhancing under-
standing of the maternal epidemiologic features involved.
Methods
Population studied
Between April 2005 and April 2007, a cross-sectional, pro-
spective study was performed on 71 pregnant women
(mean age 24.6 ± 7.7 years, 14–41 years) with a prior his-
tory of HPV infection (n = 22), or who had abnormal
Papanicolaou smear (n = 20) or genital warts (n = 29),
due to the high probability that they could have HPV
infection. The women were referred from the Obstetrical
Service of the University of Caxias do Sul and by the Basic
Health Units of the Single Health System in Caxias do Sul.
This study was performed with the approval of the Ethics
in Research Committee at the University of Caxias do Sul,
and of the Editorial and Scientific Board of the General
Hospital of Caxias do Sul, and did not present a conflict
of interest. The Letter of Free and Informed Consent and
the epidemiological evaluation tool were obtained from
all the women by individual interviews during the obstet-
rical examinations. Sixty-three (79.7%) of the 71 pregnant
women selected who entered the study underwent deliv-
ery and 16 (20.3%) dropped out of the study.
Epidemiological evaluation
The epidemiological study was performed taking the fol-
lowing variables into account: age, race, level of educa-
tion, smoking, marital status, age at first sexual
intercourse, parity, number of sexual partners in lifetime,
number of sexual  partners in past year, frequency of con-
dom use with sexual partners in lifetime, frequency of
condom use with sexual partners in past year, marital sta-
bility in years, history of immunodepression (HIV –
acquired immunodeficiency syndrome), type of HPV
lesion (genital warts, LGSIL – low-grade squamous
intraepithelial lesions, HGSIL – high-grade squamous
intraepithelial lesions), site of HPV lesion (cervical, vagi-
nal, vulvar and perineal), type of HPV infection (single,
double and multiple), gestational age at the time HPV
infection was diagnosed (weeks), duration of labor (min-
utes), time of amniotic membrane rupture (minutes),
type of delivery (cesarean section, vaginal and vaginal
with forceps) and HPV lesion at delivery (genital warts,
LGSIL – low-grade squamous intraepithelial lesions,
HGSIL – high-grade squamous intraepithelial lesions).
Sampling methods
Maternal genital
The maternal genital samples were obtained during preg-
nancy, at the first visit, when the woman was recruited.
The sample was obtained using a special brush for
cytopathological sampling of the cervix, which was used
for genital brushing in the following order: cervix and pos-
sible clinical and subclinical lesions of the vagina, vulva
and perineal region. The brush was placed in a TE solution
(Tris HCl, pH 7.5 – 10 mM; EDTA, 1 mM), and the mate-
rial collected was kept frozen at -20°C, until the desoxyri-
bonucleic acid (DNA) was extracted.
Peripheral blood maternal
Immediately before delivery (pre-partum period), a sam-
ple of peripheral blood was obtained from the woman
using a 3 ml disposable syringe (27/5 needle), retrieving
about 1 ml of blood which was placed in a KMA type tube
with EDTA. The blood collected was kept frozen at -20°C,
until DNA was extracted.
In newborns, in the first minutes of the life, buccal, body,
nasopharyngeal aspirates and arterial blood from the
umbilical cord samples were obtained.
Buccal and body
The swabs were collected in the first minutes of life, using
the special brush for cytopathological sampling of the cer-
vix, with which brushing was performed in the following
order: buccal cavities, axillary and inguinal regions of theVirology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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newborn. The brush was placed in a TE solution (Tris HCl,
pH 7.5 – 10 mM; EDTA, 1 mM) and kept frozen at -20°C,
until DNA was extracted.
Nasopharyngeal aspirates
The distal extremity of the tracheal aspiration catheter (n°
6 or 8, Sondas Descartáveis Mercosul ® Linha Sondas Des-
cartáveis Mercosul®, Empresa CPL Medical's Produtos
Médicos LTDA), used to aspirate the upper airways
(nasopharyngeal) of the newborn immediately after birth,
was removed. The distal extremity of the catheter (about 4
cm long) was cut and placed in TE solution (Tris HCl, pH
7.5 – 10 mM; EDTA, 1 mM), keeping it frozen at -20°C,
until DNA was extracted.
Arterial blood from the umbilical cord
The sample was collected directly from one of the arteries
of the cord using a 3 ml disposable syringe (27/5 needle)
to obtain about 1 ml of fetal blood. The collection was
performed after clamping the cord and complete delivery
of the placenta and fetal membranes. The fetal blood was
placed in a KMA type tube with EDTA and frozen at -
20°C, until DNA was extracted.
The placental sampling methods were performed imme-
diately after complete delivery and cleaning of the placen-
tal disk sides, using surgical compresses.
Placental swabs
The swabs were obtained using special brushes for the
cytopathological collection from the cervix, by brushing
in the following order: initially on the fetal side of the pla-
centa, and later with a new brush, on the maternal side of
the placenta. The brushes were placed individually in a TE
solution (Tris HCl, pH 7.5 – 10 mM; EDTA, 1 mM), keep-
ing them frozen at -20°C, until DNA was extracted.
Placental biopsy
Two biopsies were performed on the sides of the placental
disk: one in the more central portion; another in the more
peripheral portion (placental border). The biopsies were
performed with the help of the rat-tooth forceps, and the
curved iris scissors. The fragments collected were placed
individually in a TE solution (Tris HCl, pH 7.5 – 10 mM;
EDTA, 1 mM) and kept frozen at -20°C, until DNA was
extracted.
DNA extraction
DNA was extracted from the blood and tissue samples
using the Wizard Genomic DNA Purification Kit (Promega),
according to the manufacturer's specifications. In the
brush samples, DNA was extracted using 600 μl of NaOH
50 mM stirred in a vortex for 5–10 seconds and later incu-
bated at 95°C for 5 minutes. The solution was then neu-
tralized with 60 μl of Tris HCl pH 8.0 and kept in a freezer
at -20°C, until it was submitted to the next stages.
After the DNA extraction methodology, the products were
submitted to two different PCR methods to identify and
type the HPV DNA: multiplex PCR and type specific
nested multiplex-PCR.
β-globin and HPV amplification
The DNA samples obtained using the extraction method-
ology were amplified in multiplex PCR, and this was com-
posed by the PCO4 oligonucleotides (CAA CTT CAT CCA
CGT TCA CC) e GH20 (GAA GAG CCA AGG ACA GGT
AC), which amplified the segment of 268 base pairs (pb)
of the human β-globin gene, ensuring the qualification
and quantification of DNA for HPV analysis, and by the
PGM09 and PGMY11 oligonucleotides, which amplify a
segment of 450 pb of a preserved region of gene L1 of
Human Papillomavirus[27]. The thermocycler, model
PTC100 (MJResearch, Watertown, Mass.) was used for
amplification; the parameters for denaturation, annealing
and lengthening of the ribbons were the following: 95°C
for 5 minutes, followed by 40 51°C cycles for 30 seconds,
55°C for 1 minute, 72°C for 1 minute and, finally, 72°C
for 5 minutes. Negative and positive controls were
included with all amplifications, and the negative control
was constituted by all elements except genomic DNA; and
the positive control was constituted by HPV DNA type 16,
extracted from cells of the SiHa strain (Ludwig Institute
for Cancer Research). Four μg of the molecular DNA of the
DNA φ X 174RF HaeIII molecular weight marker were
used. The presence or absence of HPV DNA fragments and
β-globin amplified from the oligonucleotides was ana-
lyzed in 1.5% agarose gel, in buffer TBE 0.5× with 0.3%
ethidium bromide (0.1 mg/μL solution), under ultravio-
let light.
Viral typing
The HPV positive samples were submitted to a new type
of PCR, specific for viral type identification. For this pur-
pose the RFLP (Restriction Fragment Length Polymor-
phism) technique was used, according to the
methodology described by Bernard et al (1994) [28]. The
amplified product was digested by the BamHl, Ddel,
Haelll, HinfI, PstI, RsaI and SauAIII enzymes and ana-
lyzed by vertical electrophoresis in 4% polyacrylamide gel
(20.3% acrylamide, 0.7 bisacrylamide, 0.07% ammo-
nium persulphate, TBE 1X TEMED 0.7 μL/mL – Gibco-
BRL). The pGEM (PROMEGA) was used as a molecular
weight marker. Later the samples in polyacrylamide gel
were stained with silver nitrate and the fragments
obtained compared to the prototypes described by Ber-
nard et al. (1994) [28].Virology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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Amplification by nested-PCR in region E6/E7 of the HPV
The nested multiplex PCR (NMPCR) assay combines
degenerate E6/E7 consensus primers and type-specific
primers (MY09/11 and GP5+/6+) for the detection and
typing of HPV genotypes 6/11, 16, 18, 31, 33, 35, 39, 42,
43, 44, 45, 51, 52, 56, 58, 59, 66 and 68. With regard to
sensitivity and performance with clinical samples, the
novel NMPCR assay is a potentially useful tool for HPV
DNA detection in epidemiologic and clinical follow-up
studies, especially when accurate HPV typing and the
detection of multiple HPV infections are required.
The samples were amplified during the first PCR reaction
using the degenerated primers GP-E6-3F (GGG WGK KAC
TGA AAT CGG T), GP-E6-5B (CTG AGC TGT CAR NTA
ATT GCT CA) and GP-E6-6B (TCC TCT GAG TYG YCT
AAT TGC TC), W being A/T; K, G/T; R, A/G; Y, C/T and N,
A/C/G/T. These primers amplify a 630 pb region in the
E6/E7 region of the 38 most common types of HPV. The
nested-PCR reaction is specific and was performed for the
following types: 6/11, 16, 18, 31, 33, 42, 52 and 58, which
represent the most prevalent viral types in the region[29].
The primers used and the sizes of the amplified products
are shown in table 1. The entire procedure, both the first
reaction (PCR) and the second reaction (nested-PCR)
occurred according to Sotlar et al., 2004[30].
Transplacental transmission
In the study, the transplacental transmission of HPV was
considered when HPV DNA type-specific agreement was
observed between the samples: (1) mother (genital or
peripheral blood), placental and newborn (buccal, body
or cord blood); or (2) mother (genital or peripheral
blood) and newborn (cord blood)[19].
Vertical HPV transmission
In the study, vertical HPV transmission was considered
when HPV DNA was found in newborns (cord blood or
nasopharyngeal aspirates or buccal and body).
Statistical analysis
Statistical analyses were performed with the SPSS compu-
ter software package (version 12.0 for Windows). Fre-
quency tables were analyzed by using the chi-square test,
with Pearson and likelihood ratio tests for the significance
of differences between the categorical variables. The 95%
confidence interval (95% CI) was calculated where appro-
priate. Differences in the means of continuous variables
between the groups were analyzed by using nonparamet-
ric tests. In all analyses probability values of < 0.05 were
regarded as significant.
Results
The study included 49 pairs of mothers and newborns.
HPV DNA in maternal genitalia
HPV DNA was detected in 49 (77.8%) of the 63 pregnant
women who underwent delivery. The most frequently
detected types of HPV DNA were 6/11 (20.7%), 42
(15.9%), 16 (15.9%), 18 (11%), 58 (6.1%) and 31, 35 e
52 (3.7% each). Of these 54.9%, 1.2%, 40.2% and 3.7%
were types considered to present a high carcinogenic risk,
possible high risk, low risk and HPV DNA present but not
classified for viral type respectively (Table 2). Genital
infections produced by a single type of HPV DNA
(38.8%), by two types of HPV DNA (30.6%) and more
than two types of HPV DNA (30.6%) were identified.
HPV DNA in the placenta
HPV DNA was detected in 12 placentas (24.5%) of the 49
HPV DNA positive pregnant women (HPV DNA+) who
Table 1: Sequences of type-specific nested PCR primers used in this study.
HPV genotype Primer sequences Amplicon (pb)
6/11 TGC AAG AAT GCA CTG ACC AC
TGC ATG TTG TCC AGC AGT GT
334 pb*
16 CAC AGT TAT GCA CAG AGC TGC
CAT ATA TTC ATG CAA TGT AGG TGT A
457 pb
18 CAC TTC ACT GCA AGA CAT AGA
GTT GTG AAA TCG TCG TTT TTC A
332 pb
31 GAA ATT GCA TGA ACT AAG CTC G
CAC ATA TAC CTT TGT TTG TCA A
263 pb
33 ACT ATA CAC AAC ATT GAA CTA
GTT TTT ACA CGT CAC AGT GCA
398 pb
42 CCC AAA GTA GTG GTC CCA GTT A
GAT CTT TCG TAG TGT CGC AGT G
277 pb
52 TAA GGC TGC AGT GTG TGC AG
CTA ATA GTT ATT TCA CTT AAT GGT
229 pb
58 GTA AAG TGT GCT TAC GAT TGC
GTT GTT ACA GGT TAC ACT TGT
274 pb
* Base pairs.Virology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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underwent delivery. The fetal side of the placenta pre-
sented HPV DNA+ in 5 cases (41.7%, n = 5/12), the
maternal placental side in 2 cases (16.7%, n = 2/12),
while in 5 cases (41.7%, n = 5/12) research for HPV DNA
was positive on both sides of the placenta. The viral types
identified in the placentas were 6/11 (50%, n = 6/12), 16
(25%, n = 3/12), 18 (16.7%, n = 2/12), 42, 52 and 58
(8.3%, n = 1/12 – each). The type specific HPV concord-
ance among the genital/placental samples was 91.7% (n =
11/12). Seven placentas (58.3%, n = 7/12) presented viral
types considered a high carcinogenic risk (types 16, 18, 52
and 58) and 2 placentas presented two different types of
HPV DNA (Table 3).
It was observed that seven (58.2%, n = 7/12) cases pre-
sented HPV DNA+ for the genital/placental/newborn
samples and five (41.7%, n = 5/12) cases presented HPV
DNA+ for the genital/placental samples with negative
research for HPV DNA in newborns (NB).
HPV DNA in newborns
HPV DNA was identified in eleven NB (22.4%, n = 11/
49). Five NB had HPV DNA+ in samples of nasopharyn-
geal aspirate, six in buccal and body scrapings, and three
in arterial cord blood (Table 3). The viral types identified
were 6/11 (45.5%, n = 5/11), 42 (18.2%, n = 2/11), 52
(18.2%, n = 2/11), 18 and 59 (9.1%, n = 1/11 – each).
Four NB (36.4%, n = 4/11) presented viral types consid-
ered a high carcinogenic risk (types 18, 52 and 59). In one
NB two types of HPV DNA were detected (types 6/11 and
52).
Among the eleven cases of NB HPV DNA+, seven (63.6%,
n = 7/11) presented HPV DNA+ for the genital/placental/
NB samples. Six of these cases (85.7%, n = 6/7) were in
concordance as to the type-specific HPV among the pla-
cental/NB samples and five cases (71.4%, n = 5/7) pre-
sented concordance as to the type specific HPV among the
genital/placental/NB samples, suggesting the transplacen-
tal transmission of the virus (10.2%, n = 5/49).
No physical abnormalities or genital warts were observed
in the 49 newborns.
Among the 11 cases of NB HPV DNA+ (vertical transmis-
sion), four (36.4%, n = 4/11) did not present transplacen-
tal infection due to virus (Table 3). Of these, one case
presented type specific HPV concordance among the gen-
ital/arterial cord blood samples (HPV type 52) suggesting
the possibility of transplacental transmission. Among the
three other cases, two had type specific HPV concordance
among the genital/NB samples (HPV types 11 and 42).
On the other hand, five NB (41.7%, n = 5/12) were nega-
tive for HPV DNA research, while in their respective pla-
centas HPV DNA+ was shown (Table 3). The HPV
identified were types 16 (40%, n = 2/5), 6/11, 18 and 58
(20%, n = 1/5 – each). Four NB (80%, n = 4/5) presented
viral types considered a high carcinogenic risk (types 16,
18, 58). The concordance of type specific HPV observed
among the genital/placental samples was 100% (n = 5/5).
HPV DNA in arterial cord blood
Studying the arterial blood from the umbilical cords of
NB (Table 3), 3 cases (6.1%, n = 3/49) HPV DNA+ for
viral types 6/11, 18 and 52 were observed. In 2 clinical
cases there was concordance of type specific HPV among
the genital/placental/arterial cord blood samples, and in
the other case, concordance of type specific HPV among
the genital/arterial cord blood was observed. The latter
case mentioned, which corresponds to the same case men-
tioned above, was considered transplacental transmission
(hematogenic, directly through the placenta, without any
infection in the latter). Of the 3 cases studied, two
(66.7%) had HPV DNA types 18 and 52 considered a high
carcinogenic risk.
HPV DNA in maternal peripheral blood
Three (6.1%, n = 3/49) parturients had HPV DNA in their
peripheral blood (Table 3). In two cases HPV DNA that
Table 2: HPV types in maternal genital sample.
HPV DNA
Type
n = 18
Carcinogenic risk Frequency
n = 82
%
6/11 LR 17 20.7
42 LR 13 15.9
16 HR 13 15.9
18 HR 9 11
58 HR 5 6.1
31 HR 3 3.7
35 HR 3 3.7
52 HR 3 3.7
51 HR 2 2.4
54 LR 2 2.4
59 HR 2 2.4
26 PHR 1 1.2
33 HR 1 1.2
34 HR 1 1.2
45 HR 1 1.2
68 HR 1 1.2
70 LR 1 1.2
73 HR 1 1.2
NC* - 3 3.7
The HPV types were identified by both multiplex PCR and nested 
multiplex PCR methods. *NC = HPV DNA positive but could not be 
classified by type. LR – Low-risk HPV genotypes (HPV type 6, 11, 40, 
42, 43, 44, 54, 61, 70, 72, 81 and CP6108). HR – High-risk HPV 
genotypes (HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 
73 and 82). PHR – Probable high-risk HPV genotypes (HPV type 26, 
53 and 66) [61].V
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Table 3: Clinical and laboratory history of genital HPV infection during pregnancy and delivery and distribution of HPV types in maternal, newborn and placental samples.
Epidemiology maternal HPV type in samples
Pregnancy Delivery Maternal Placental Newborn
Case HPV lesion type HPV lesion site Type HPV lesion Genital Peripheral blood Fetal side Maternal side Aspirates nasopharyngeal Buccal and body Cord blood
Biopsy Brush Biopsy Brush
Border Central Border Central
1W a r t s V V V N o 6 / 1 1
2 HGSIL C C No 16+6/11 6/11 6/11 6/11 6/11
3 HGSIL C C Yes 16+31 16
4 Warts VV V No 16+42+54 16 42+16 42
5 LGSIL C C Yes 18
6 Warts VV C No 6/11+16+31
7 Warts C+VV+VG V No 6/11+42 6/11 6/11 6/11 6/11
8 HGSIL C C Yes 52 6/11 6/11+52 6/11
9 LGSIL C V Yes 42+51+NC*
10 Warts VV+VG V No 6/11
11 LGSIL C V No 18 18 18 18 18
12 Warts VV V+F No NC*
13 LGSIL C C Yes 6/11+42
14 LGSIL C C Yes 16+42+58 6/11 59
15 Warts C+VV+VG V Yes 6/11+42
16 Warts VV+VG C No 6/11
17 HGSIL C C Yes 18+51
18 Warts VV+P C No 42+59
19 Warts VV V No 6/11 6/11
20 HGSIL C C No 42+35
21 Warts VV C Yes 52 52
22 Warts VV C Yes 34
23 Warts VV+VG V Yes 18V
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24 Warts VV V No 16+73 16
25 Warts VV+VG C No 68
26 Warts C V Yes 6/11+16 16
27 Warts C+VV+VG V No 16+58
28 Warts VV C Yes 6/11+33
29 LGSIL C V No 16
30 LGSIL C V Yes 52+42+58+54 58
31 LGSIL C C No 16
32 Warts VV C No 6/11
33 HGSIL C V Yes 18 18
34 Warts VV V Yes 11 11
35 Warts VV+VG C Yes 42 42
36 LGSIL C V Yes 16
37 HGSIL C C Yes 58 6/11+52
38 HGSIL C V No 6/11+18
39 HGSIL C C Yes 18+31
40 Warts VV V No 6/11 6/11
41 Warts VV C No 42+35+NC*
42 LGSIL C C Yes 42
43 LGSIL C C yes 16+18+42
44 LGSIL C+VV+VG C Yes 18+26
45 Warts VV V Yes 6/11+58+59 6/11 6/11 6/11 6/11 6/11
46 Warts VV+VG C Yes 6
47 Warts VV V Yes 35
48 Warts VV V No 70
49 Warts VV+VG V No 6+45 58
The HPV types were identified by both multiplex PCR and nested multiplex PCR methods. *NC = HPV DNA positive but could not be classified by type.
Type of delivery = C – cesarean section; V- vaginal; and V+ F – vaginal with forceps.
HPV lesion site = C – cervical; VG – vaginal; VV – vulva; P – perineal.
HPV lesion type = Warts – genital warts; LGSIL – low-grade squamous intraepithelial lesions; HGSIL – high-grade squamous intraepithelial lesions.
Table 3: Clinical and laboratory history of genital HPV infection during pregnancy and delivery and distribution of HPV types in maternal, newborn and placental samples. (Continued)Virology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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was considered a high carcinogenic risk (types 16 and 58)
was detected. There was 66.7% (n = 2/3) concordance of
type specific HPV among the maternal genital/peripheral
blood samples. In all three cases no HPV DNA was identi-
fied in the respective placentas and NB.
Statistical analysis showed a significant association
between placental HPV infection and the epidemiological
variable history of immunodepression (HIV, p = 0.011),
as observed in table 4 and 5.
In the group of pregnant women negative for genital HPV
DNA (n = 14/63), it was observed that all samples, both
of maternal peripheral blood and those of nasopharyn-
geal aspirate, buccal and bodily scrapings and arterial cord
blood and those of placental biopsies and scrapings pre-
sented negative results for HPV DNA research.
HPV detection and typing methods
Evaluating the HPV DNA detection and typing methods,
it was observed that the multiplex PCR methodology
identified HPV DNA in 41 pregnant women (83.7%, n =
Table 4: HPV status of the placenta and maternal factors.
Maternal variable Placental HPV DNA infection
Positive (n = 12) Negative (n = 37)
Age (years)
≤ 19 6 (50%) 17 (45.9%)
≥ 20 to ≤ 29 3 (25%) 12 (32.4%)
≥ 30 to ≤ 39 2 (16.7%) 7 (18.9%)
≥ 40 to ≤ 49 1( 8 . 3 % )1 ( 2 . 7 % )
Mean for placental HPV DNA positive group (24.3 ± 8.3 years) - - - -
Mean for placental HPV DNA negative group (23.8 ± 8.2 years) - - - -
Race
White 11 (91.7%) 33 (89.2%)
Non-white 1 (8.3%) 4 (10.8%)
Level of education
Illiterate --- -
Elementary (complete or incomplete) 6 (50%) 22 (59.4%)
High school (complete or incomplete) 5 (41.7%) 15 (40.5%)
College (complete or incomplete) 1 (8.3%) - -
Smoking
No 10 (83.3%) 24 (64.9%)
< 10 cigarettes per day - - 6 (16.2%)
≥ 10 cigarettes per day 2 (16.7%) 7 (18.9%)
Marital status
Married 3 (25%) 8 (21.6%)
Single 2 (16.7%) 9 (24.3%)
Cohabiting 6 (50%) 19 (51.4%)
Divorced, separated 1 (8.3%) 1 (2.7%)
Marital stability (years)
≤ 2 8 (66.7%) 26 (70.3%)
≥ 3 to ≤ 5 3 (25%) 7 (18.9%)
≥ 6 1 (8.3%) 4 (10.8%)
Mean for placental HPV DNA positive group (3.1 ± 4.3 years) - - - -
Mean for placental HPV DNA negative group (2.8 ± 4.7 years) - - - -
History of Immunodepression (HIV)*
No 10 (83.3%) 37 (100%)
Yes 2( 1 6 . 7 % ) - -
Data are reported as number and percentage (in parentheses) of placental positive or negative infection for human papillomavirus. *P < 0.011 
indicates a statistically significant difference between the positive and negative groups by Pearson's chi-square test (HIV – acquired 
immunodeficiency syndrome).Virology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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Table 5: HPV status of the placental and delivery factors.
Maternal variable Placental HPV DNA infection
Positive (n = 12) Negative (n = 37)
Type of HPV lesion
Genital warts 5 (41.7%) 23 (62.2%)
LGSIL1 3 (25%) 9 (24.3%)
HGSIL2 4 (33.3%) 5 (13.5%)
Site of HPV lesion
Uterine cervix 8 (66.7%) 13 (35.1%)
Vulva 3 (25%) 13 (35.1%)
Vulva + vagina - - 7 (18.9%)
Vulva + perineal region --1 ( 2 . 7 % )
Uterine cervix + vulva + vagina 1 (8.3%) 3 (8.1%)
Type of HPV Infection
Single 3 (25%) 16 (43.2%)
Double 2 (16.7%) 13 (35.1%)
Multiple 7 (58.3%) 8 (21.6%)
Type of delivery
Vaginal 8 (66.7%) 15 (40.5%)
Vaginal + forceps --1 ( 2 . 7 % )
Cesarean section 4 (33.3%) 21 (56.8%)
Mean gestational age of the delivery in the placental HPV DNA positive group (39.7 ± 1.1 weeks)
Mean gestational age of the delivery in the placental HPV DNA negative group (39.2 ± 2.4 weeks)
Gestational age at the time HPV infection was diagnosed (week)
≥ 4 to ≤ 12 2 (16.7%) 17 (45.9%)
≥ 13 to ≤ 28 4 (33.3%) 8 (21.6%)
≥ 29 to ≤ 42 1 (8.3%) 6 (18.9%)
Prior to pregnancy 5 (41.7%) 5 (13.5%)
Mean in the placental HPV DNA positive group (10.5 ± 13.3 weeks)
Mean in the placental HPV DNA negative group (14.63 ± 12 weeks)
Time of RUPREME3 (min)
≤ 360 11 (100%) 35 (92.1%)
≥ 361 to ≤ 720 --1 ( 2 . 6 % )
≥ 721 --2 ( 5 . 3 % )
Mean of placental HPV DNA positive group (37 ± 37 minutes) - - - -
Mean of placental HPV DNA negative group (106 ± 244 minutes) - - - -
Duration of labor (min)
≤ 240 6 (54.5%) 22 (57.9%)
≥ 241 to ≤ 360 2 (18.2%) 10 (26.3%)
≥ 361 3 (27.3%) 6 (15.8%)
Mean of placental HPV DNA positive group (236 ± 196 minutes) - - - -
Mean of placental HPV DNA negative group (185 ± 203 minutes) - - - -
HPV lesion at delivery
Yes 7 (58.3%) 19 (51.4%)
No 5 (41.7%) 18 (48.6%)
Data are reported as number and percentage (in parentheses) of infection placental positive or negative for human papillomavirus. *P < 0.05 
indicates a statistically significant difference between the positive and negative groups by Pearson's chi-square test. 1Low-grade squamous 
intraepithelial lesions. 2High-grade squamous intraepithelial lesions. 3RUPREME = rupture of membrane amniotic.Virology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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41/49), in 31 pregnant women (75.6%, n = 31/41) only a
single type of HPV DNA was identified, and two or more
types of HPV in 10 pregnant women (24.4%, n = 10/41).
The nested multiplex PCR method (although it was used
to identify and type 9 types of HPV shown as the most
prevalent in the city of Caxias do Sul) identified HPV DNA
in 43 pregnant women (87.8%, n = 43/49), only a single
type of HPV DNA in 28 pregnant women (83.7%, n = 28/
43), and two or more types of HPV in 15 pregnant women
(83.7%, n = 15/43). Together the multiplex PCR and
nested multiplex PCR methods identified HPV DNA in 49
pregnant women (100%, n = 49/49), only a single type of
HPV DNA in 19 pregnant women (38.8%, n = 19/49) and
two or more types of HPV in 30 pregnant women (61.2%,
n = 30/49).
The multiplex PCR method identified HPV DNA in only
two newborns (18.2%, n = 2/11), while the nested multi-
plex PCR method identified it in 9 newborns (81.8%, n =
9/11).
In the placentas, multiplex PCR identified HPV DNA in
only a single one (83.7%, n = 1/12), while the nested mul-
tiplex PCR method identified HPV in 12 cases (100%, n =
12/12).
Discussion
Human papillomavirus infection is one of the most fre-
quent sexually transmitted diseases [31-33]. Non-sexual
transmission[34] of HPV may occur directly by contact
with the skin or mucosas (between people or by self-inoc-
ulation), or indirectly through contaminated objects, or
still during the perinatal period.
Perinatal transmission may occur: (1) directly, during the
passage of the fetus through the birth canal and on com-
ing into contact with infected maternal secretions[13,18];
in delivery by cesarean section by ascending infection
from the vaginal canal, after a premature rupture of the
amniotic membranes [35]; in managing the mother with
the baby (changing nappies, bathing)[10]; (2) indirectly,
during vaginal delivery from contaminated objects; and
(3) intrauterine transmission at the time of fertilization
from sperm carrying latent HPV[36]; ascending infection
from secretions of the maternal genital tract; and transpla-
cental[11,19].
HPV DNA in pregnant women
HPV DNA was detected in 49 pregnant women (77.8%, n
= 49/63). The percentage found was considered high com-
pared to the existing literature. However, given the origin
of the population studied, from outpatient clinics dealing
with prenatal examinations and infectious diseases, these
figures were already expected. The data regarding the prev-
alence of HPV infection in pregnancy are highly discord-
ant: 5.4% reported by Tenti et al. (1997)[37] and 68.8%
mentioned by Cason et al. (1995)[15]. The diversity of
percentages observed is related to different factors that by
themselves could influence the results, such as: diagnostic
techniques, the characteristics of the samples and the
inclusion criteria. Eppel et al. (2000)[16] observed a
24.6% prevalence of HPV infection in the uterine cervix of
pregnant women. Recently, Takakuwa et al. (2006)[38],
examining the cervical smears of 1.183 pregnant women
for HPV DNA using the PCR-RFLP methods, observed a
prevalence of 22.6% in pregnant women aged less than 25
years. This percentage was statistically significant (p <
0.0005) compared to the percentage obtained in pregnant
women over the age of 25 years (11.3%), and it was con-
cluded that the prevalence of HPV is considered high in
young Japanese pregnant women.
Studying the type of lesion produced by HPV in the mater-
nal genitalia, it was observed that 57.1% had genital
warts, 24.5% low grade cervical intraepithelial lesions,
and 18.4% high grade cervical intraepithelial lesions,
results which could suggest a higher percentage of HPV
DNA considered a low carcinogenic risk, which, however,
was not observed. Of the HPV DNA types detected 54.9%,
1.2% and 40.2% were viral types considered a high carci-
nogenic risk, possible high risk and low risk, respectively.
Genital infections produced by two or more types of HPV
DNA were identified in 61.2% of the cases. Lu et al.
(2003)[39] studying the prevalence and viral type in preg-
nant women with a diagnosis of squamous atypias of the
uterine cervix detected HPV DNA in 88.6% of the cases. Of
the HPV positive cases, 79.6%, 4.3% and 5.4% were con-
sidered a high carcinogenic risk, probable high risk and
low risk, respectively. The most frequent viral types
detected were 52 (31.2%), 16 (15.1%), 39 (11.8%), 53
(10.8%), and 18 and 58 (9.7% each). Viral infection by
multiple types was detected in 43% of the cases. Hernan-
dez-Giron et al. (2005)[40], in a population study in Méx-
ico detected high carcinogenic risk HPV DNA in 37.2% of
274 pregnant women and 14.2% of 1,060 non-pregnant
women.
Infections by multiple types of HPV are considered rela-
tively common among the population in general[41].
Thomas et al. (2000)[42] reported that infection by mul-
tiple types of HPV are acquired more frequently than
expected. These authors suggested that populations with a
specific sexual behavior of exposing themselves to an
ensemble of different types of HPV, or else the preexist-
ence of a type of HPV could make it easier to acquire a new
type of virus through an as yet unknown mechanism.
Other authors[43] disagreed with the above statements
and suggested that the risk factors are the same, both to
acquire a single infection or a multiple one for HPV. A few
authors suggested several hypotheses to account for theVirology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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high rates of HPV infection observed in pregnant women,
such as the immunosuppressive and hormonal states
induced by pregnancy[40,44]. These hypotheses could
also explain the rate of multiple HPV infection (61.2%)
observed in this study.
HPV DNA in the placenta
The use of different methods to sample the placentas was
determinant for a more accurate identification of HPV
DNA in third trimester pregnancy placentas (24.5%, n =
12/49). The results show that the isolated use of scraping
methods or biopsies, especially if applied only to one of
the sides of the placental disk, would detect a smaller
number than the total obtained in this study.
The viral types identified in the placentas were 6/11 (50%,
n = 6/12), 16 (25%, n = 3/12), 18 (16.7%, n = 2/12), 42,
52 and 58 (8.3%, n = 1/12 – each). The HPV DNA identi-
fied in the placentas were 6/11, 16, 18, 52 and 58. Seven
placentas (58.3%, n = 7/12) presented HPV considered a
high carcinogenic risk (types 16, 18, 52 and 58) and two
(16.7%, n = 2/12) presented two different types of HPV
DNA. The presence of HPV DNA in the placenta indicates
the possibility of transplacental exposure to viral infection
and to the need of considering the possible consequences
of this exposure during the period: (1) intrauterine, to
miscarriages[45] and possible malformations[16]; (2)
postnatal period to genital warts in childhood[46], in
adolescence juvenile-onset recurrent papillomatosis[5];
(3) in lifetime, the possible transmission of the carcino-
genic agent[47,48].
In addition, the concordance observed in the type specific
HPV between the genital/placental samples (91.7%, n =
11/12), strongly suggests that the HPV DNA detected in
the placenta comes from maternal viral infection. This
placental infection could be the result of an ascending
canalicular infection from genital secretions (transamni-
otic) or hematogenic. The difference found in the types of
HPV DNA may be due to different causes, such as contam-
ination of the samples (unlikely), infection from the
semen at the time of fertilization, infection due to multi-
ple types, or subtypes and/or variants of HPV. Eppel et al.
(2000)[16] in their study on HPV DNA detection in pla-
centas, did not identify them in any of the 147 samples of
chorionic vilosity collected by transabdominal amniocen-
tesis. Even so, the authors suggested the possibility of
transplacental viral transmission.
HPV DNA in newborns
As seen in the evaluation of methods to sample the pla-
centa, the use of different sampling methods in the NB
was determinant for a more precise identification of the
percentage of vertical transmission of HPV (22.4%, n =
11/49). The results show that the isolated use of oral and
bodily cavity scraping methods, or nasopharyngeal aspi-
rates, or arterial cord blood, if applied individually for
clinical screening would detect a smaller number of NB
HPV DNA+ than the total obtained in this study.
The viral types identified in the NB were 6/11 (45.5%, n =
5/11), 42 (18.2%, n = 2/11), 52 (18.2%, n = 2/11), 18 and
59 (9.1%, n = 1/11 – each). Genital warts, which are
caused by HPV types 6 or 11, are considered a frequent
complication in pregnancy and clinically important due
to the possibility of vertical transmission. Armstrong et al.
(2000)[49] considered juvenile recurrent respiratory pap-
illomatosis a consequence of vertical transmission of
HPV. However, the risk of developing this complication
in a child born to a mother infected with HPV is one to
several hundred exposures[50]. Smith et al. (1995)[51]
showed a rate of only 1% of vertical transmission of HPV
DNA. Other authors reported higher percentages, using
the PCR methodology for HPV type 16 and 18 in genital
scrapings and oral cavity of mother/NB pairs, respectively,
and detected vertical transmission rates between 31% and
73%[13,15,18,52,53].
Four NB (36.4%, n = 4/11) presented viral types consid-
ered a high carcinogenic risk (types 18, 52 and 59) and
one presented two different types of HPV DNA (types 6/
11 and 52). These data are sufficient evidence to confirm
the perinatal transmission of HPV, considered a high car-
cinogenic risk. These findings require future studies to be
able to establish: (1) the significance and consequences of
infection in the child; (2) their relationship with the infec-
tions detected in adults; (3) the risk for the development
of cancer in lifetime. The virus infects mainly the epithe-
lial cells, where it may remain latent for a very long time,
evolve to the subclinical form, and thus remain, or reacti-
vate, with a resulting accumulation of chromosomal
mutations in host cells. The next result after this accumu-
lated latent carcinogenic potential of certain types of HPV
during childhood would be the development of a neo-
plasm in lifetime. The natural history of papilloma infec-
tion is characterized by regression in a period that varies
from months to years[54].
In 5 cases (41.7%, n = 5/12) concordance of type specific
HPV was observed between the genital/'placental/NB
samples and in 1 case (8.3%, n = 1/12) between the geni-
tal/arterial cord blood samples, suggesting that there is
often placental transmission (50%, n = 6/12). This was
the first study in third trimester placentas to suggest the
percentage of transplacental transmission of HPV DNA.
Several authors have focused special attention on the
mode of HPV transmission. In 1992, Tseng et al.[19] sug-
gested transplacental transmission of the virus, after
detecting the same viral genome (HPV type 16) in cervi-Virology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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covaginal smears, in mononuclear cells of peripheral
blood of fifteen pregnant women and in the cord blood of
seven newborns from these same mothers. Favre et al.
(1998)[11] showed the presence of several types of HPV
DNA in amniotic liquid, placental cells and cervicovaginal
smears of a mother and newborn with epidermodisplasia
verruciforme. Hermonat et al. (1997)[25] recorded that the
infection of HPV was three times more prevalent in speci-
mens of spontaneous abortion in the first trimester. Later,
in 1998, the same authors[55], confirmed the presence of
HPV DNA in placental tissue of spontaneous abortions
and concluded that the predominant site for HPV DNA
type 16 findings were the cells of the syncytiotrophoblast.
Thus, they raised the hypotheses of viremia, not yet con-
vincingly documented, and of contamination of placental
cells by oocyte infection before or right after implanta-
tion, by ascending infection or by infection carried by
sperm containing latent HPV.
This study pointed to five cases of NB (41.7%, n = 5/12)
negative for the research of HPV DNA, while in their
respective placentas HPV DNA was detected. Four of these
placentas presented viral types considered a high carcino-
genic risk (types 16, 18, 58), and 100% (n = 5/5) of type
specific HPV concordance is observed among the genital/
placental specimens. The results achieved show that trans-
mission of the virus to the fetus is not a prerogative of
every HPV DNA+ woman, or in all cases of HPV DNA+
placentas, pointing to the existence of other as yet
unknown factors that could be involved in transplacental
transmission. Sedlacek et al. (1989)[56] detected the pres-
ence of HPV DNA in the oral cavity of 36.5% of the new-
born, delivered vaginally to mothers with a diagnosis of
HPV DNA+ for cervical cells. Kaye et al. (1994)[57]
showed that the pregnant women who transmitted the
virus to their concepts had a higher viral load.
Among the eleven cases of RN HPV DNA+ (vertical trans-
mission), four cases (36.4%, n = 4/11) did not present
HPV DNA in their respective placentas. One case out of
this total presented type-specific HPV concordance
between the genital/arterial cord blood (HPV type 52)
and two presented concordance of type specific HPV
between the genital/NB samples (HPV types 11 and 42).
These results emphasized the possibility that other HPV
transmission routes exist during pregnancy (transamni-
otic ascending infection), or during labor (ascending
infection after the amniotic membranes are ruptured), or
during delivery (by the fetus passing through the contam-
inated birth canal).
HPV DNA in arterial cord blood and HPV DNA in maternal 
peripheral blood
Three cases of NB (6.1%, n = 3/49) who presented HPV
DNA+ in arterial cord blood samples were seen. The three
cases were considered transplacental transmission due to
finding concordance of the type specific HPV among the
genital/NB samples. In these three cases, as in all cases of
vertical transmission, no HPV DNA was detected in mater-
nal peripheral blood. On the other hand, three cases
(6.1%, n = 3/49) were also observed of parturients who
had HPV DNA in their peripheral blood, without HPV
DNA in the respective placentas and NB. These results sug-
gest that HPV infections in the placentas may have
occurred by another route, which was not hematogenic,
either by an infection that was already present before preg-
nancy in the endometrium, or by an ascending infection
during the egg implantation period, or at the time of ferti-
lization by sperm contaminated by the virus, or else dur-
ing pregnancy facilitated by the uterine anatomy. The
HPV predilection for tissues, apparently exclusive to the
pavement epithelium of the skin and the mucosas, has
been challenged in the last few years, since several studies
demonstrated the capacity of HPV to infect different sites.
The studies of Teseng et al. (1992)[19] may be mentioned,
who demonstrated the presence of HPV in the amniotic
liquid of pregnant women before labor, and Hermonat et
al. (1998)[55] who described the presence of HPV in the
syncytiotrophoblast of spontaneous abortions, proving
the capacity of HPV to locate also in the uterine cavity.
These studies showed the capacity of the virus to infect the
uterine cavity, and therefore it is no surprise that the virus
appears in the endometrium. Fedrizzi et al. (2004)[58]
found HPV DNA (types 16 and 18) in 10% of the women
with a normal endometrium. The exception is the work by
Lai et al. (1992)[59] who found HPV DNA in 70% of the
cases studied that had a normal endometrium or some
benign disease. However, O'Leary et al. (1998)[60] did
not find HPV DNA in the normal endometrium.
The positive and significant correlation between placental
HPV infection and the maternal epidemiological variable
"history of immunodepression" (HIV, p = 0.011), may be
related to the special characteristics of the gravid cycle,
especially the changes in the hormonal and immunologi-
cal balance prevailing during this period, which might
favor placental HPV infection.
HPV detection and typing methods
Although the nested multiplex PCR methodology is used
to identify and type only 9 types of HPV shown as the
most prevalent in the city of Caxias do Sul, it performed
very well in identifying maternal HPV DNA, and also con-
siderably increased the number of pregnant women with
multiple virus infections. In the newborn and placental
samples the nested multiplex PCR method showed its
great sensitivity and specificity to identify HPV. The use of
that method was also crucial to evaluate the concordance
of type specific HPV DNA among the maternal/placental/Virology Journal 2008, 5:106 http://www.virologyj.com/content/5/1/106
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newborn samples, thus defining the vertical and transpla-
cental transmission rates of the virus.
Concluding, the HPV DNA detection rate in the placenta
was 24.5% (n = 12/49) and the transplacental transmis-
sion rate was 12.2% (n = 6/49). A transplacental transmis-
sion rate of 54.5% (n = 6/11) was observed when only the
cases of vertical transmission were analyzed. These results
were achieved in analyses of the placentas and newborns
of mothers with genital warts or intraepithelial lesions of
the uterine cervix. Thus, different forms of management
can be adopted for each of these different stages (pre-ges-
tational, gestation, delivery and the first few months after
delivery), both from the diagnostic and therapeutic per-
spective. The mother and the newborn must be observed
clinically and educational preventive measures must be
established concerning the forms of HPV transmission,
besides effective strategies for specific immunization.
In future, the HPV DNA rates in must be observed in the
normal endometrium of women of reproductive age, in
order to explain the possible route of infection by conti-
nuity and/or contiguity between the endometrium and
conception products.
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